Shahzadi, Iram
Zwanenburg, Alex
Lattermann, Annika
Linge, Annett
Baldus, Christian
Peeken, Jan C.
Combs, Stephanie E.
Diefenhardt, Markus
Rödel, Claus
Kirste, Simon
Grosu, Anca-Ligia
Baumann, Michael
Krause, Mechthild
Troost, Esther G. C.
Löck, Steffen
Funding for this research was provided by:
Federal Ministry of Education and Research (03WKDB2D)
Technische Universität Dresden
Article History
Received: 11 February 2022
Accepted: 17 May 2022
First Online: 17 June 2022
Competing interests
: Dr. Baumann, CEO and Scientific Chair of the German Cancer Research Center (DKFZ, Heidelberg) is responsible for collaborations with a large number of companies and institutions worldwide. In this capacity, he has signed contracts for research funding and/or collaborations, including commercial transfers, with industry and academia on behalf of his institute(s) and staff. He is a member of several supervisory boards, advisory boards, and boards of trustees. Dr. Baumann confirms that there is no conflict of interest for this paper. Dr. Baumann confirms that, to the best of his knowledge, none of the above funding sources were involved in the preparation of this paper. Dr. Krause received funding for her research projects by IBA (2016), Merck KGaA (2014–2018 for preclinical study; 2018–2020 for clinical study), Medipan GmbH (2014–2018), Attomol GmbH (2019–2021), GA Generic Assays GmbH (2019–2021), BTU Cottbus-Senftenberg (2019–2021), Gesellschaft für medizinische und wissenschaftliche genetische Analysen (2019–2021), Lipotype GmbH (2019–2021), PolyAn GmbH (2019–2021). Dr. Troost received funding for her research projects by Merck KGaA (since 2017 for clinical study), Medipan GmbH (2014–2018), Attomol GmbH (2019–2021), GA Generic Assays GmbH (2019–2021), BTU Cottbus-Senftenberg (2019–2021), Gesellschaft für medizinische und wissenschaftliche genetische Analysen (2019–2021), Lipotype GmbH (2019–2021), PolyAn GmbH (2019–2021), by Astra Zeneca (since 2019 for clinical study). Dr. Linge received funding for her research projects by Attomol GmbH (2019–2022), GA Generic Assays GmbH (2019–2022), BTU Cottbus-Senftenberg (2019–2022), Gesellschaft für medizinische und wissenschaftliche genetische Analysen (2019–2022), Lipotype GmbH (2019–2022), PolyAn GmbH (2019–2022). In the past 5 years, Dr. Claus Rödel, received funding for his clinical research projects by the German Cancer Aid. Dr. Zwanenburg, Dr. Lattermann, Dr. Baldus, Dr. Peeken, Dr. Combs, Dr. Diefenhardt, Dr. Kirste, Dr. Grosu, Dr. Löck and Iram Shahzadi declare no potential conflict of interest.